Understanding Insulin Pumps and Continuous Glucose Monitoring Systems

by

Table of Contents

Understanding Insulin Pumps and Continuous Glucose Monitoring Systems: A Comprehensive Guide to Modern Diabetes Management

Diabetes management has undergone a remarkable transformation over the past two decades, with technological innovations fundamentally changing how people with diabetes monitor and control their blood sugar levels. Insulin administration and blood glucose monitoring have transformed from multiple finger pricks in a day to a few swipes on a cell phone. At the forefront of this revolution are insulin pumps and continuous glucose monitoring (CGM) systems—sophisticated medical devices that work together to provide unprecedented control over blood glucose levels while reducing the daily burden of diabetes management.

For millions of people living with type 1 diabetes and many with type 2 diabetes requiring insulin therapy, these technologies represent more than just convenience. They offer the possibility of achieving optimal glycemic control while minimizing the risk of dangerous hypoglycemic episodes and long-term complications. Automated insulin delivery (AID) is now the recommended standard of care for people with type 1 diabetes and for those with type 2 diabetes on multiple daily injections (ADA Standards of Care 2026: Section 7). This comprehensive guide explores everything you need to know about insulin pumps and CGM systems, from basic functionality to the latest innovations shaping the future of diabetes care.

What Are Insulin Pumps?

An insulin pump is a small computerized device that’s worn continuously and gives insulin through a thin tube placed under the skin. Unlike traditional insulin therapy that requires multiple daily injections with syringes or insulin pens, insulin pumps provide a continuous, automated delivery system that more closely mimics the natural insulin secretion pattern of a healthy pancreas.

How Insulin Pumps Work

It works all day delivering insulin (basal insulin) and can give extra doses of insulin (bolus) at mealtimes or when your blood glucose (blood sugar) is high. The pump stores rapid-acting insulin in a reservoir and delivers it through a thin plastic tube (catheter) connected to a small cannula inserted just beneath the skin, typically on the abdomen, thigh, or upper arm.

Insulin pumps use rapid-acting insulin. This type of insulin starts working quickly and can be delivered in small, steady amounts all day (basal insulin) and in larger amounts at mealtimes or to correct high blood glucose (bolus insulin). Users program their pump with personalized settings based on their individual insulin requirements, carbohydrate ratios, and correction factors, allowing for highly customized diabetes management.

Types of Insulin Pumps Available in 2026

The insulin pump market has diversified significantly, offering options to suit different lifestyles and preferences. Traditional (tubed) pumps: External device with tubing and an infusion set delivering basal and bolus insulin. Patch (tubeless) pumps: Adhesive devices worn on the skin, controlled by an app or device. These are discreet and easy for active lifestyles.

Tubed Insulin Pumps

Traditional tubed pumps consist of a separate pump device connected to the infusion site via flexible tubing. These systems typically offer larger insulin reservoirs and touchscreen interfaces for direct control. The t:slim X2 features a bright touchscreen display and uses the same Control-IQ+ algorithm as the Mobi. Its larger 300-unit reservoir is ideal for individuals with higher insulin needs. The t:slim X2 is compatible with Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus in the U.S., offering users the widest CGM options among any Tandem pump.

MiniMed 780G uses Medtronic’s SmartGuard™ algorithm, including advanced features like Meal Detection and frequent (every ~5 minutes) adjustments based on CGM readings. It also supports an extended infusion set worn up to ~7 days, meaning fewer site changes. This extended wear capability represents a significant advancement in reducing the burden of site changes for pump users.

Tubeless Patch Pumps

Tubeless or patch pumps eliminate external tubing by integrating the insulin reservoir and delivery mechanism into a single adhesive device worn directly on the skin. The Omnipod 5 holds up to 200 units of U-100 rapid-acting insulin per Pod, which lasts for up to three days. While it holds a significant amount, it is not the largest capacity on the market compared to some tubed pumps that hold 300 units.

The tubeless design offers particular advantages for active individuals, swimmers, and those who prefer a more discreet insulin delivery system. These devices are typically controlled via a separate handheld device or smartphone application, providing flexibility in how users interact with their pump.

Emerging Insulin Pump Technologies

The insulin pump landscape continues to evolve rapidly. The Niia system from Swiss company PharmaSens might be the first to fully combine a pump and CGM into a single patch. Controlled entirely through a smartphone app, Niia is screenless, sleek, and designed to streamline diabetes care by reducing the number of devices a person wears. This integration represents the next frontier in diabetes technology, potentially reducing device burden while maintaining sophisticated automated insulin delivery capabilities.

Sigi (Tandem): A tubeless-first pump with a reusable body and swappable insulin cartridges. This innovative approach addresses environmental concerns while potentially reducing long-term costs for users by allowing them to reuse the pump body while replacing only the insulin cartridges and adhesive components.

Benefits of Insulin Pump Therapy

Insulin pump therapy offers numerous advantages over traditional multiple daily injection (MDI) regimens:

  • Precise Insulin Delivery: Pumps can deliver insulin in increments as small as 0.01 or 0.025 units, allowing for much more precise dosing than is possible with injections
  • Flexible Basal Rates: Users can program different basal insulin rates throughout the day to match their body’s changing insulin needs
  • Reduced Injection Burden: Instead of multiple daily injections, users only need to change their infusion site every 2-7 days depending on the system
  • Improved Quality of Life: Unlike multiple daily shots, the pump lets you adjust insulin doses easily for meals, exercise, or changes in your routine, like sleeping in or being active.
  • Better Glycemic Control: The Tandem t:slim X2 has been known to significantly increase time-in-range, while reducing high and low glucose levels.

Understanding Continuous Glucose Monitoring Systems

Diabetes management technology has advanced significantly in recent decades, with continuous glucose monitoring (CGM) leading this evolution. The development of CGM has brought about substantial changes in diabetes management, transforming how patients and healthcare providers approach glucose monitoring and therapeutic decision-making.

How CGM Systems Work

Continuous Glucose Monitors · CGMs are small, wearable devices that continuously measure a person’s blood-glucose levels. They are largely used in place of finger sticks. CGM systems consist of three main components: a small sensor inserted just under the skin that measures glucose levels in the interstitial fluid, a transmitter that sends glucose data wirelessly, and a receiver or smartphone app that displays the glucose readings and trends.

The sensors are connected through a needle or a catheter, which transmits glucose levels to a receiver or smartphone app, eliminating the need for frequent and invasive finger pricks. They are normally replaced every 7 to 14 days to ensure continuous and reliable monitoring. Some newer systems offer even longer wear times, with implantable sensors lasting up to 90 days or more.

The sensor measures glucose levels in the interstitial fluid—the fluid that surrounds the cells in your body—rather than directly in the blood. While there is typically a slight lag time between blood glucose and interstitial glucose levels (usually 5-10 minutes), modern CGM systems have become remarkably accurate and reliable for diabetes management decisions.

Clinical Benefits of CGM Technology

Continuous glucose monitoring (CGM) has well-established reliability and efficacy in terms of improving A1c, reducing hypoglycemia, and improving the time in target glucose range. The clinical evidence supporting CGM use has grown substantially, leading to its recognition as a standard of care for many people with diabetes.

Studies report consistent glycosylated hemoglobin reductions of 0.25%–3.0% and notable time in range improvements of 15%–34%. CGM effectively reduces hypoglycemic events, with studies reporting significant reductions in time spent in hypoglycemia. These improvements translate to better long-term health outcomes and reduced risk of diabetes complications.

Real-Time Glucose Monitoring and Alerts

One advantage of using a CGM or glucose monitoring device is the continuous tracking, which provides a comprehensive view of blood glucose levels. This can help people with diabetes better understand how their bodies respond to food, physical activity, and medication. It can also help them identify patterns and trends that may go unnoticed with traditional blood glucose meter monitoring. CGMs also help reduce the risk of low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia) by providing real-time alerts when glucose levels are out of range.

These customizable alerts can warn users before glucose levels become dangerously high or low, allowing for proactive intervention rather than reactive treatment. This predictive capability is particularly valuable for preventing severe hypoglycemia, especially during sleep when traditional monitoring methods are impractical.

Educational Value and Lifestyle Insights

CGM also serves as an educational tool for lifestyle modification, providing real-time feedback that helps patients understand how diet and physical activity affect glucose levels. This immediate feedback loop empowers people with diabetes to make informed decisions about their food choices, exercise timing, and insulin dosing, leading to improved self-management skills over time.

CGM Metrics: Understanding Time in Range

Modern diabetes management has shifted from relying solely on hemoglobin A1c measurements to incorporating CGM-derived metrics that provide a more comprehensive picture of glycemic control. The most important of these metrics is Time in Range (TIR).

The American Diabetes Association (ADA) recommends assessing overall glucose levels using the A1c and/or CGM metrics such as % Time in Range (TIR, the % of time spent 70-180 mg/dL) for most adults with diabetes. Time in Range has emerged as a powerful predictor of long-term complications and provides actionable information for day-to-day diabetes management decisions.

CGM reports also typically include Time Below Range (TBR), which measures hypoglycemia, and Time Above Range (TAR), which measures hyperglycemia. Together, these metrics provide a nuanced understanding of glucose control that a single A1c value cannot capture, revealing patterns of variability and specific times of day when glucose control is problematic.

Recent Advances in CGM Technology

The mid-2000s to early 2010s was a time of rapid advancement in CGM technology, with improvements in both sensor accuracy and user experience. Dexcom introduced its SEVEN system in 2007, extending the wear time of CGM sensors to seven days. This was followed by the SEVEN PLUS in 2009, which offered more accurate readings and additional features such as trend graphs and alarms for high or low blood glucose levels.

Today’s CGM systems have become increasingly sophisticated, with several notable improvements:

  • Extended Wear Time: Medtronic touts it as the world’s smallest, thinnest, most discreet sensor, with a wear time of up to 15 days.
  • Improved Accuracy: Modern sensors require little to no calibration and provide highly accurate readings across a wide range of glucose values
  • Smaller Form Factor: That sensor, the GS3, is only 2.9mm thick and weighs 1.5g, making it light enough to blend seamlessly into a wearable pump.
  • Over-the-Counter Availability: The recent FDA approval of over-the-counter CGM devices represents a significant milestone, making this technology more accessible to a broader range of patients.

Expanding Applications Beyond Type 1 Diabetes

CGM has progressed from an optional technology to a recommended standard of care for many patients with diabetes. Currently, it is not only strongly recommended for patients with type 1 diabetes (T1D) but also considered essential technology for patients with type 2 diabetes (T2D) on insulin therapy. Clinical guidelines now recognize CGM as a fundamental component of comprehensive diabetes care for these populations, recognizing its role in improving glycemic outcomes and reducing complications.

The company says that new registry data demonstrates that long-term use of the Dexcom G7 CGM supports weight management and lowers A1C for people with type 2 diabetes who aren’t on insulin therapy. This expanding evidence base suggests that CGM benefits extend beyond insulin users, potentially helping a much broader population manage their diabetes effectively.

Automated Insulin Delivery: The Integration of Pumps and CGM

An automated insulin delivery (AID) system has three main components: an insulin pump, a continuous glucose monitor (CGM), and an algorithm that determines the best insulin dose to help keep you in range. AIDs are also known as artificial pancreas or closed-loop systems. This integration represents one of the most significant advances in diabetes technology, fundamentally changing the paradigm of diabetes management.

How Automated Insulin Delivery Systems Work

Automated insulin delivery systems, also known as hybrid closed-loop systems, mimic physiological glucose regulation by using algorithms to continuously adjust insulin based on CGM readings, residual insulin action, and other inputs such as meal intake and exercise announcement. The system continuously monitors glucose levels through the CGM, and the algorithm makes automatic adjustments to insulin delivery every few minutes based on current glucose levels, glucose trends, and predicted future glucose values.

Automated Insulin Delivery systems combine a CGM, an insulin pump, and an algorithm to automatically fine-tune insulin delivery throughout the day and night. They’re sometimes called “hybrid closed-loop” systems because they still require manual input for meals, but they reduce the mental load of background insulin adjustments.

It’s important to understand that most current systems are “hybrid” closed-loop, meaning they still require user input for meals and certain other situations. You still need to practice daily T1D management (carb counting, bolusing, adjusting for exercise, etc.) However, the system handles the complex task of adjusting basal insulin delivery automatically, which represents a significant reduction in the cognitive burden of diabetes management.

Leading AID Systems Available in 2026

Tandem Control-IQ Technology

Control-IQ is a leading hybrid closed-loop system used with Tandem t:slim X2 and Tandem’s Mobi pumps. Control-IQ algorithm: It predicts glucose levels 30 minutes in advance and automatically adjusts basal insulin every five minutes, and can deliver correction boluses (up to once per hour) to help keep users in a safe target range. This predictive capability allows the system to prevent both hyperglycemia and hypoglycemia before they occur, rather than simply reacting to current glucose levels.

Omnipod 5 Automated Mode

The Omnipod 5 combines the convenience of tubeless insulin delivery with automated insulin delivery capabilities. In trials, users with type 1 diabetes who did not deliver insulin before meals saw their time-in-range improve from 37% to 57%. Type 2 participants saw similar gains. These impressive results demonstrate the power of automated insulin delivery even without perfect meal bolusing.

Medtronic SmartGuard Technology

The 780G system offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. When paired with 780G, Instinct provides real-time glucose readings, helping the pump automate its insulin adjustments and delivery. The meal detection feature represents an important step toward reducing the burden of meal announcements, automatically detecting and responding to post-meal glucose rises.

Beta Bionics iLet Bionic Pancreas

iLet is designed to be even more “hands-off” than traditional AID systems — it adapts insulin delivery based on body weight and CGM data without requiring preset basal rates or complex settings. Some versions emphasize minimal manual correction and learning insulin patterns automatically, making it a promising choice for people who want more automation and less micromanagement. This simplified approach may be particularly beneficial for newly diagnosed individuals or those who struggle with the complexity of traditional pump therapy.

Twiist AID System

Twiist uses the Tidepool Loop algorithm to automatically adjust insulin delivery every five minutes based on CGM data. It’s one of the first pumps to measure insulin flow and volume for each microdose directly, improving dosing accuracy. Interesting Fact: The Twiist pump is the first commercial pump built around the open-source Loop algorithm ecosystem, which many people in the DIY diabetes community had been using unofficially for years. That’s why some endocrinologists see it as a major shift toward more customizable automated insulin delivery systems.

Clinical Outcomes with Automated Insulin Delivery

Advanced algorithms that adjust insulin dosing to maintain glucose levels within a target range can minimize the risks of hypoglycemia/hyperglycemia and keep blood glucose in range. Clinical studies have shown significant improvements in glycemic control across different age and groups of patients.

The benefits of AID systems extend beyond improved glucose metrics. Users consistently report reduced diabetes distress, improved sleep quality, and greater confidence in their diabetes management. The systems work continuously, including overnight, providing protection against nocturnal hypoglycemia that has historically been one of the most feared complications of intensive insulin therapy.

AID systems and virtual platforms made it possible to achieve target glycosylated hemoglobin in diabetes while minimizing hypoglycemia, which has always been challenging in T1DM. This achievement represents a fundamental shift in what is possible with insulin therapy, allowing people with diabetes to achieve near-normal glucose levels without the constant fear of severe hypoglycemia.

The Future of Diabetes Technology: Fully Closed-Loop Systems

While current hybrid closed-loop systems have dramatically improved diabetes management, the field continues to advance toward fully automated systems that require minimal user input.

Fully Closed-Loop Technology

At ATTD 2026, CamDiab introduced CamAPS Liberty, a fully closed-loop feature for its CamAPS FX app. The integration of Liberty — which the company labeled the world’s first fully closed-loop feature — supports users with type 1 diabetes when daily demands prove challenging. It pauses the need to count carbohydrates or deliver meal boluses, fully automating insulin delivery. When activated, a user can enable a fully closed-loop mode, eliminating the need to count carbohydrates or deliver a pre-meal insulin bolus.

This represents a significant milestone in diabetes technology. While users may still choose to announce meals for optimal control, the system can function effectively without this input, dramatically reducing the cognitive burden of diabetes management. EVOLUTION 2 marks the second in a series of feasibility studies support the development of a fully closed-loop Omnipod system.

Dual-Hormone Systems

Moreover, AID systems currently in testing aim to improve upon current systems by adding one additional hormone, glucagon, that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas. These dual-hormone systems would deliver both insulin to lower glucose and glucagon to raise it, providing even tighter glucose control and additional protection against hypoglycemia.

Non-Invasive Glucose Monitoring

CGM continues to experience significant advancements aimed at developing lower-cost, more accurate and user-friendly sensing technologies. While current state-of-the-art CGM systems predominantly rely on invasive measurement techniques, there is growing interest in noninvasive glucose monitoring solutions. An accurate and reliable noninvasive glucose monitoring device would offer substantial benefits in ease of use and accessibility.

Multiple companies and research institutions are working on non-invasive glucose monitoring technologies using various approaches, including optical sensors, radiofrequency analysis, and other innovative methods. While significant technical challenges remain, successful development of accurate non-invasive CGM would represent a transformative advancement, potentially expanding glucose monitoring to even broader populations.

Choosing the Right System: Factors to Consider

With numerous insulin pump and CGM options available, choosing the right system can feel overwhelming. Several factors should guide your decision-making process.

Lifestyle Considerations

Activity Level and Physical Demands

Your daily activities significantly influence which system might work best. Athletes and highly active individuals often prefer tubeless patch pumps that eliminate concerns about tubing getting caught or disconnected during physical activity. Conversely, some users prefer tubed pumps because they can temporarily disconnect them for contact sports or water activities without wasting an entire pump site.

Discretion and Visibility

Some people prefer the discretion of tubeless pumps that can be worn entirely under clothing, while others don’t mind the visibility of tubed pumps and may even view their diabetes technology as a conversation starter or advocacy opportunity. Consider your personal comfort level with visible medical devices and how this might vary in different settings (work, social situations, intimate relationships).

Technology Comfort Level

Different systems require varying levels of technological engagement. Some pumps feature touchscreens and extensive customization options, while others prioritize simplicity with smartphone control and minimal on-device interfaces. Consider your comfort with technology and whether you prefer hands-on control or automated decision-making.

Medical Considerations

Insulin Requirements

Your total daily insulin dose influences pump selection. If you require large amounts of insulin, you’ll need a pump with a larger reservoir capacity (typically 300 units) to avoid frequent reservoir changes. Conversely, if you use small amounts of insulin, you might prioritize a pump that can deliver very small basal rates and bolus increments with high precision.

Hypoglycemia Awareness

People with impaired hypoglycemia awareness—those who don’t reliably feel symptoms when their blood sugar drops—benefit tremendously from CGM systems with predictive low glucose alerts and automated insulin delivery systems that can suspend or reduce insulin delivery before hypoglycemia occurs. For these individuals, AID systems aren’t just convenient; they’re potentially life-saving.

Glycemic Variability

If you experience significant glucose variability despite your best efforts with traditional therapy, automated insulin delivery systems may provide substantial benefits. The continuous micro-adjustments these systems make can smooth out glucose fluctuations that are difficult to manage with manual insulin dosing.

Practical Considerations

Insurance Coverage and Cost

Insurance coverage varies significantly between different pump and CGM systems. Before falling in love with a particular device, verify your insurance coverage, including copays, deductibles, and whether the device is covered under your pharmacy or durable medical equipment benefit. Despite high initial costs, CGM’s prevention of complications and hospitalizations ultimately reduces healthcare expenditures.

Healthcare Provider Experience

Your diabetes care team’s experience with different systems matters. While most endocrinologists and diabetes educators work with multiple systems, they may have particular expertise with certain platforms. Their familiarity can significantly impact the quality of support you receive, especially during the initial learning period and when troubleshooting issues.

Device Ecosystem and Compatibility

The strength of these systems lies in integration — the pump needs real-time glucose info to adjust insulin delivery automatically. Many of the pumps above pair with the Dexcom G6 or G7 sensors, which transmit readings every ~5 minutes. Some systems also work with other sensors like the FreeStyle Libre 3 Plus, depending on region and prescription. Consider which CGM sensors work with your preferred pump, as this integration is crucial for automated insulin delivery functionality.

Getting Started with Pump and CGM Therapy

Transitioning to insulin pump and CGM therapy requires preparation, education, and ongoing support. Understanding what to expect can help ensure a successful transition.

The Evaluation Process

If you think an automated insulin delivery system or insulin pump might be right for you, speak with your healthcare provider. Consult the Breakthrough T1D Health Insurance Guide to learn about insurance coverage for T1D management tools and therapies.

Your healthcare provider will assess whether you’re a good candidate for pump and CGM therapy based on several factors, including your current diabetes management, A1c levels, history of hypoglycemia, lifestyle factors, and motivation to use the technology effectively. This evaluation typically includes discussions about your diabetes management goals, challenges you face with current therapy, and expectations for what pump and CGM therapy can achieve.

Training and Education

Comprehensive training is essential for successful pump and CGM use. Most diabetes centers provide structured education programs that cover device operation, carbohydrate counting, insulin dosing calculations, troubleshooting, and interpreting CGM data. This training typically occurs over multiple sessions and may include both individual and group components.

High satisfaction rates and long-term use suggest that device-related issues are manageable with proper education and support. Initial training is just the beginning; ongoing education and support are crucial for optimizing therapy and adapting to new features and capabilities as they become available.

Moreover, the combined effect of CGM and education have been shown to improve glycemic outcomes more than CGM alone. This underscores the importance of not just having the technology, but understanding how to use it effectively and interpret the data it provides.

The Adjustment Period

Expect an adjustment period when starting pump and CGM therapy. It typically takes several weeks to become comfortable with device operation and several months to fully optimize settings. During this time, you’ll work closely with your diabetes care team to fine-tune basal rates, insulin-to-carbohydrate ratios, and correction factors.

For CGM users, learning to interpret glucose trends and respond appropriately takes practice. The constant stream of glucose data can initially feel overwhelming, but most users quickly learn to focus on trends and patterns rather than individual readings. Setting appropriate alert thresholds is also important—too sensitive, and you’ll experience alert fatigue; too lenient, and you’ll miss important warnings.

Living with Insulin Pumps and CGM: Practical Tips

Site Selection and Rotation

Proper site selection and rotation are crucial for maintaining good insulin absorption and preventing complications like lipohypertrophy (fatty lumps under the skin) or skin irritation. For insulin pump infusion sets, common sites include the abdomen, upper buttocks, thighs, and upper arms. CGM sensors can typically be worn on the abdomen, upper arms, or other areas with adequate subcutaneous tissue.

Rotate sites systematically, avoiding the same spot for at least two weeks. Keep a mental or written map of your sites to ensure adequate rotation. If you notice decreased insulin effectiveness, increased glucose variability, or visible skin changes, these may indicate the need for more aggressive site rotation or evaluation by your healthcare provider.

Managing Skin Issues

While skin-related complications remain a concern, technological advancements have addressed many initial concerns. Common skin issues include adhesive reactions, irritation from cleaning agents, and mechanical irritation from devices. If you experience skin problems, consider using barrier wipes or patches under devices, trying different adhesive products, or consulting with your healthcare team about alternative sites or devices.

Some users develop contact dermatitis from adhesives. If this occurs, hypoallergenic barrier products can often allow continued device use. In severe cases, switching to a different device with different adhesive materials may be necessary.

Exercise and Physical Activity

Exercise presents unique challenges for insulin pump and CGM users, but these technologies also provide powerful tools for managing exercise-related glucose changes. Many pumps offer temporary basal rate reductions or exercise modes that can help prevent exercise-induced hypoglycemia. CGM data showing glucose trends during and after exercise helps you learn your individual patterns and adjust your approach accordingly.

For high-intensity or contact sports, you may need to temporarily disconnect your pump or protect it with specialized cases. CGM sensors are generally durable enough for most activities, though some users apply additional adhesive patches for extra security during vigorous exercise or water activities.

Travel Considerations

Traveling with diabetes technology requires planning but is entirely manageable. Always carry backup supplies, including extra infusion sets, reservoirs, sensors, and traditional insulin delivery methods (syringes or pens) in case of device failure. Carry a letter from your healthcare provider explaining your medical devices, especially for air travel security screening.

Most insulin pumps and CGM systems can safely go through airport security scanners, though some manufacturers recommend requesting hand inspection instead. Never pack insulin or diabetes supplies in checked luggage, as temperature extremes in cargo holds can damage insulin and devices.

When traveling across time zones, work with your healthcare team to develop a plan for adjusting pump settings. Many modern pumps make this relatively straightforward, but planning ahead prevents confusion and potential glucose control issues.

Troubleshooting Common Issues

Unexplained High Blood Glucose

If your glucose levels are unexpectedly high despite appropriate insulin delivery, several issues could be responsible. Check for kinked tubing, air bubbles in the reservoir or tubing, a dislodged or bent cannula, or insulin that has been exposed to extreme temperatures. Twiist features proprietary iiSure™ sound wave technology for high-precision, direct, minute-by-minute dosing measurements, enabling up to 9x faster detection of insulin blockages. This type of advanced monitoring can help identify delivery problems more quickly.

If you can’t identify an obvious problem, change your infusion set and reservoir. If high glucose persists, inject insulin with a syringe or pen to rule out insulin degradation, and contact your healthcare provider if problems continue.

Occlusion Alarms

Occlusion alarms indicate that insulin cannot flow freely through the infusion set. This might result from kinked tubing, a bent cannula, scar tissue at the insertion site, or crystallized insulin blocking the cannula. When you receive an occlusion alarm, change your infusion set immediately and check your glucose level. You may need to give a correction bolus with a syringe or pen if your glucose has risen significantly.

Sensor Accuracy Problems

While modern CGM systems are highly accurate, occasional discrepancies between CGM readings and fingerstick blood glucose values can occur. Remember that CGM measures interstitial glucose, which lags behind blood glucose by several minutes, particularly when glucose is changing rapidly. If you suspect accuracy issues, confirm with a fingerstick test before making treatment decisions.

Factors that can affect sensor accuracy include sensor placement (avoid areas with poor circulation or significant fat deposits), dehydration, certain medications (particularly acetaminophen with some sensors), and sensor age (accuracy may decline near the end of the wear period).

Sensor Failures and Early Terminations

Occasionally, sensors fail prematurely or provide unreliable data. This might result from sensor damage during insertion, placement in an area with poor blood flow, or manufacturing defects. Most manufacturers will replace failed sensors if you contact their customer support. Keep records of sensor failures, as patterns might indicate the need for different placement sites or techniques.

Compression Lows

Some CGM users experience false low readings when lying on their sensor during sleep, called “compression lows.” This occurs when pressure on the sensor temporarily restricts interstitial fluid flow. If you notice a pattern of low readings that resolve when you change position and aren’t confirmed by symptoms or fingerstick tests, compression lows may be the culprit. Consider placing sensors in locations less likely to be compressed during sleep.

The Impact on Quality of Life and Diabetes Distress

Beyond the clinical metrics of improved A1c and time in range, insulin pumps and CGM systems profoundly impact the daily lived experience of diabetes.

Reduced Diabetes Burden

These advances in technology could reduce the burden associated with insulin treatment for diabetes. The constant mental calculations required for diabetes management—counting carbohydrates, calculating insulin doses, predicting the impact of exercise, worrying about hypoglycemia—create significant cognitive burden. Automated insulin delivery systems shoulder much of this burden, making continuous micro-adjustments that would be impossible to achieve manually.

Many users report feeling “freed” from the constant vigilance diabetes demands. While they still need to engage with their diabetes management, the technology handles the background adjustments that previously required constant attention. This mental relief often translates to improved emotional well-being and reduced diabetes distress.

Sleep Quality and Nocturnal Safety

Perhaps no aspect of diabetes technology has more dramatically improved quality of life than overnight glucose management. Parents of children with type 1 diabetes often describe years of sleep deprivation from checking blood glucose multiple times each night. CGM alarms and automated insulin delivery systems provide reassurance and actual protection against nocturnal hypoglycemia, allowing both people with diabetes and their caregivers to sleep more soundly.

The predictive low glucose suspend features in many systems can prevent hypoglycemia before it occurs, while automated insulin delivery systems continuously adjust insulin delivery throughout the night to maintain stable glucose levels. This overnight protection is often cited as one of the most valuable benefits of diabetes technology.

Social and Psychological Aspects

The visibility of diabetes technology can have complex psychological and social implications. Some people, particularly adolescents, may feel self-conscious about visible devices. Others embrace their devices as part of their identity or as tools for diabetes advocacy. The increasing prevalence of diabetes technology has helped normalize visible medical devices, and many users report positive interactions when others notice and ask about their devices.

Remote monitoring features in many systems allow parents, partners, or other caregivers to view glucose data from their own devices. This can provide peace of mind and enable support, though it’s important to establish boundaries and communication patterns that respect the autonomy of the person with diabetes while providing appropriate support.

Access and Equity Challenges

Despite the transformative potential of insulin pumps and CGM systems, significant barriers to access remain.

Cost and Insurance Coverage

Although CGMs have revolutionised diabetes management and diabetes self-management, barriers exist to accessing this technology, particularly in low- and middle-income countries (LMICs). In higher-income settings, insurance coverage can limit access to CGMs and related supplies, leading to financial barriers for people with diabetes and healthcare facilities. In LMICs, the affordability of devices and healthcare infrastructure challenges limit access to CGM technology. These constraints are compounded by healthcare professionals’ need for specialised training and resources to support people with diabetes in effectively using CGMs for personalised diabetes care.

Even in countries with relatively robust healthcare systems, insurance coverage for diabetes technology varies widely. Some insurance plans readily cover pumps and CGM systems, while others impose restrictive criteria or high out-of-pocket costs. Use of CGM is increasing, however not all who could benefit from the technology have access. This report details the results of a study assessing the impact that utilization barriers and restricting prescriber choice have on patient’s access to technology and health outcomes.

Cost and access to CGM systems continue to be significant barriers; however, public funding initiatives have helped reduce socioeconomic disparities in managing both type 1 and type 2 diabetes, making these life-saving technologies more accessible to diverse populations. Public funding has been instrumental in making these life-saving technologies more accessible to lower-income populations, helping to close the gap in diabetes management.

Healthcare Provider Training and Support

For healthcare professionals, CGM data can be complex to understand and use effectively, requiring specialised knowledge and training in glucose data analysis. Furthermore, integrating CGM data analysis into routine patient consultations can be time-consuming, impacting the overall efficiency of healthcare delivery.

The rapid pace of technological advancement means healthcare providers must continuously update their knowledge and skills. Not all diabetes care providers have equal access to training and support for the latest technologies, which can create disparities in the quality of care patients receive depending on where they seek treatment.

Advocacy and Policy Efforts

We are partnering with people with diabetes, health care professionals, advocacy groups, and policy makers to address CGM access for those who use Medicaid. We’re advocating for CGM coverage and working to get rid of barriers to necessary diabetes technology so people can better manage their diabetes and experience fewer poor health outcomes and premature deaths.

Continued advocacy efforts are essential to ensure that all people with diabetes who could benefit from these technologies have access to them, regardless of their insurance status, geographic location, or socioeconomic circumstances. The recognition of automated insulin delivery as the standard of care represents an important step, but translating this recommendation into universal access remains an ongoing challenge.

Emerging Technologies and Future Directions

Artificial Intelligence and Machine Learning

These programs can even help to support decision-making by artificial intelligence (AI) algorithms. Machine learning algorithms are increasingly being incorporated into diabetes management systems, learning from individual patterns to provide increasingly personalized insulin delivery and glucose predictions.

Ongoing efforts to raise awareness of CGM devices and address these barriers, coupled with advancements in machine learning and predictive analytics, will further enhance the role of CGM in improving diabetes care and patient outcomes globally. These AI-driven systems promise to continuously improve their performance over time, adapting to changes in insulin sensitivity, activity patterns, and other factors that affect glucose control.

Integration and Interoperability

In addition, cloud-based data collection programs can support diabetes and healthcare providers (HCPs) to make the optimal decision easily by offering various data from various devices such as glucose trend data, carbohydrate intake, insulin on board (IOB), and a bolus calculator in one platform. The future of diabetes technology lies not just in individual device improvements, but in seamless integration across multiple platforms and devices.

Efforts toward device interoperability—allowing different manufacturers’ pumps, CGMs, and algorithms to work together—promise to give users more choice and flexibility. This approach, sometimes called the “artificial pancreas ecosystem,” would allow users to mix and match components based on their preferences and needs rather than being locked into a single manufacturer’s ecosystem.

Expanded Applications

Furthermore, it could expand applications beyond diabetes management, enabling broader health monitoring, such as pre-diabetes assessment, sports performance optimization and monitoring of other patient groups. As CGM technology becomes more accessible and less invasive, its applications are expanding beyond traditional diabetes management.

Also, CGM is increasingly being explored for use in newborns and young infants, particularly those who are preterm or have unstable glucose levels. CGM provides real-time data on glucose levels, which can help in adjusting treatments promptly and reducing the need for frequent blood tests. This technology is especially valuable in managing neonatal hypoglycemia and hyperglycemia, conditions that can impact neurodevelopment. Despite these challenges, CGM holds promises for improving long-term outcomes in neonatal care.

Conclusion: The Transformative Power of Diabetes Technology

Continuous glucose monitoring has revolutionized the management of diabetes and is now widely acceptable. CGM offers a versatile tool for improving individual care and advancing research. Its applications extend from daily diabetes management and predictive modeling to early diagnosis, education and the development of automated systems.

Insulin pumps and continuous glucose monitoring systems represent one of the most significant advances in diabetes care since the discovery of insulin itself. These technologies have transformed diabetes from a condition requiring constant manual intervention to one where sophisticated algorithms can handle much of the minute-to-minute management, allowing people with diabetes to focus on living their lives rather than constantly managing their condition.

The development of diabetes technology made it possible to avoid hyperglycemia without increasing hypoglycemia with a more comfortable fit and less effort, which could not previously be shown in diabetes with insulin therapy. This achievement—tight glucose control without increased hypoglycemia risk—represents a fundamental paradigm shift in what is possible with insulin therapy.

The integration of insulin pumps with CGM systems through automated insulin delivery algorithms has created what many call an “artificial pancreas,” though this term somewhat oversimplifies the technology. While these systems don’t fully replicate the exquisite precision of a functioning pancreas, they come remarkably close, providing glucose control that was unimaginable just a decade ago.

Looking forward, the trajectory is clear: systems will become more automated, requiring less user input while providing better glucose control. Devices will become smaller, more comfortable, and less invasive. Integration across platforms will improve, giving users more choice and flexibility. And perhaps most importantly, access will expand, making these life-changing technologies available to more people with diabetes around the world.

With appropriate training and support, CGM represents a transformative technology for comprehensive diabetes care. The same can be said for insulin pumps and the integrated systems that combine these technologies. For people with diabetes, their families, and their healthcare providers, these tools offer not just better glucose control, but reduced burden, improved quality of life, and the freedom to live more fully without the constant shadow of diabetes management dominating every moment.

If you’re considering insulin pump or CGM therapy, or if you’re already using these technologies and want to optimize your outcomes, work closely with your diabetes care team. Stay informed about new developments and features. Connect with other users through online communities and support groups. And remember that while the technology is powerful, it’s most effective when combined with diabetes education, ongoing support, and your own expertise about your body and your diabetes.

The future of diabetes management is here, and it’s more promising than ever before. Whether you’re newly diagnosed or have been living with diabetes for decades, these technologies offer the potential for better health, reduced complications, and a life less constrained by the demands of diabetes management.

Additional Resources

For more information about insulin pumps and continuous glucose monitoring systems, consider exploring these reputable resources:

Remember that while online resources provide valuable information, they should complement, not replace, personalized medical advice from your healthcare team. Every person with diabetes is unique, and the best diabetes management approach is one tailored to your individual needs, preferences, and circumstances.